2019 Annual Meeting | C49 - Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease

Date Sunday 05/05/19

Time 01:00 PM - 03:00 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Ralph F. Jozefowicz, MD, FAAN, Adam Quick, MD

Topic(s) Multiple Sclerosis, Neuromuscular and Clinical Neurophysiology (EMG), Sleep, General Neurology: Overview

Learning Objectives Participants should be able to discern the pros and cons in selection of multiple sclerosis therapies, understand new developments in the treatment of neuromuscular disease, and be able to diagnosis and treat common sleep disorders.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:40 PM EDT	Speaker	Update in Multiple Sclerosis Michelle Fabian, MD, FAAN
01:40 PM - 02:20 PM EDT	Speaker	Update in Sleep Disorders Douglas B. Kirsch, MD, FAAN
02:20 PM - 03:00 PM EDT	Speaker	Update in Neuromuscular Disease Gil I. Wolfe, MD, FAAN

Faculty Disclosures
Ralph F. Jozefowicz, MD, FAAN	Dr. Jozefowicz has nothing to disclose.
Adam Quick, MD	The institution of Dr. Quick has received research support from NINDS. The institution of Dr. Quick has received research support from NEALS.
Michelle Fabian, MD, FAAN	Dr. Fabian has nothing to disclose.
Douglas B. Kirsch, MD, FAAN	Dr. Kirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amazon. Dr. Kirsch has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apnimed. Dr. Kirsch has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SleepImage. Dr. Kirsch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AIM. Dr. Kirsch has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for AASM. Dr. Kirsch has received publishing royalties from a publication relating to health care.
Gil I. Wolfe, MD, FAAN	Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Wolfe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ArgenX. Dr. Wolfe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB/Ra. Dr. Wolfe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Wolfe has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Cartesian. Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Grifols. The institution of Dr. Wolfe has received research support from UCB/Ra. The institution of Dr. Wolfe has received research support from Immunovant. The institution of Dr. Wolfe has received research support from Roche. Dr. Wolfe has received personal compensation in the range of $0-$499 for serving as a Advisor with FDA Advisory Panel for Cellular, Tissue and Genetic Therapies.

��ɫ��

��ɫ��